Track HLS Therapeutics's total current liabilities ($29M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
HLS Therapeutics posts a total current liabilities of $29M as of June 2026. That compares with $28M in the prior-year period — up 5.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, HLS Therapeutics's total current liabilities was $28M. The latest reading is $29M — a 5.4% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.
Total Current Liabilities is one piece of HLS Therapeutics's financial statement story. At $29M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for HLTRF's total current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; HLS Therapeutics's other metric pages and overview cover the third.